• Biogen completed its acquisition of privately held RayThera, adding small-molecule immunology programs to its pipeline.
• The deal expands Biogen’s immunology portfolio with multiple assets targeting immune-mediated conditions across several indications.
• RayThera’s lead program entered Phase 1 development in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061815PRIMZONEFULLFEED9805757) on August 06, 2026, and is solely responsible for the information contained therein.